Main area: CDU Hotline- Acute Care
Grade: NHS Medical & Dental: Senior Clinical Fellow
Contract: 12 months (Fixed Term)
Hours: Full time - 40 hours per week
Job ref: 158-24-220-CDU
Employer: The Clatterbridge Cancer Centre NHS Foundation Trust
Employer type: NHS
Site: The Clatterbridge Cancer Centre - Liverpool
Town: Liverpool
Salary: £55,329 - £63,152 per annum
Salary period: Yearly
Closing: 26/09/2024 23:59
Job overview
The Clatterbridge Cancer Centre is one of the most established immunotherapy centres in the country treating approximately 1000 new patients with immunotherapy a year. There is an extensive pan-tumour immunotherapy toxicity team managing around 200-300 patients at any one time. The Centre has pioneered the development of management protocols and production of effective management strategies and resources. There is a strong focus on immunotherapy based, early phase trials alongside the development of a clinical-scientific interface to allow the recruitment of patients with toxicity in real-time.
Main duties of the job
The role will be suitable for doctors who have completed Core Medical Training, particularly for those wishing to gain additional experience before commencing oncology training or for those already in higher speciality training looking to spend a year out of programme (OOP) to extend their knowledge of oncological service development.
The role will cover the development of the hotline triage service including internal processes, interface with CDU, interface with external trusts via Same Day Emergency Care Units and Community Response units. There will also be an element of patient assessment and review. The role is based at the Clatterbridge Cancer Centre in Liverpool.
Please note there is an optional opportunity to participate on the on-call rota within oncology throughout the year.
There will also be a strong educational emphasis to this role with involvement in our existing educational programmes and you will be encouraged to be involved in audit and quality improvement projects, research, and trials.
Key working relationships:
Medical Oncology Consultants, Clinical Oncology Consultants, Haematology Consultants, Palliative Medicine Consultants, Matron, Ward Managers, Ward and Day Unit nursing staff, Clinical fellows IMT 1/2 doctors, GP trainees, specialty ST3+ doctors, Advanced Nurse Practitioners, Clinical Nurse Specialists.
Person specification
Qualifications
* Full Registration and License to practice with the GMC
* MBCHB or equivalent
* Advanced life support
* MRCP or equivalent
Knowledge and Expertise
* Compliance with the GMC Duties of a Doctor
* Satisfactory progress in previous posts with evidence of competency at CT2/ST2 equivalent
* Previous experience in systemic anticancer therapies and/or radiotherapy
Experience
* Have sufficient experience working in medical specialties (not including foundation level experience) by the advertised post start date. This can be via either: Training completed in either core medical training, ACCS (acute medicine) or broad-based training with the further year in CT2 core medical training, or have at least 24 months’ experience in medical specialties (of which at least 12 months must include the care of acute medical in-patients).
* Appropriate experience and competence in the recognition and management of the acutely unwell patient.
* Ability to work as an effective member of a multidisciplinary team.
* Awareness of own limitations and consults senior colleagues appropriately.
* Evidence of contribution to effective clinical audit.
If you are successfully shortlisted, you will be invited for an interview via email. Please ensure you regularly check your emails (including junk folders) following your application.
The cost of processing a new DBS application is met by the successful applicant. DBS costs are recovered via salary deduction following commencement in post.
This post is subject to the Rehabilitation of Offenders Act 1974 (Exceptions) Order 1975 (Amendment) (England and Wales) Order 2020 and it will be necessary for a submission for Disclosure to be made to the Disclosure and Barring Service.
#J-18808-Ljbffr